X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (33837) 33837
Magazine Article (380) 380
Newspaper Article (380) 380
Newsletter (268) 268
Book Chapter (85) 85
Trade Publication Article (26) 26
Book / eBook (22) 22
Transcript (18) 18
Publication (17) 17
Conference Proceeding (15) 15
Reference (13) 13
Government Document (6) 6
Book Review (5) 5
Web Resource (5) 5
Dissertation (4) 4
Streaming Video (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (28244) 28244
aspirin - therapeutic use (18783) 18783
aspirin (15903) 15903
female (14555) 14555
male (14487) 14487
index medicus (11388) 11388
middle aged (9904) 9904
aged (8968) 8968
platelet aggregation inhibitors - therapeutic use (8113) 8113
adult (6518) 6518
risk factors (5523) 5523
cardiac & cardiovascular systems (4182) 4182
treatment outcome (4099) 4099
animals (4021) 4021
aspirin - adverse effects (3975) 3975
prevention (3730) 3730
aspirin - administration & dosage (3692) 3692
drug therapy, combination (3618) 3618
anticoagulants - therapeutic use (3607) 3607
risk (3574) 3574
ticlopidine - analogs & derivatives (3474) 3474
clopidogrel (3432) 3432
pharmacology & pharmacy (3407) 3407
ticlopidine - therapeutic use (3224) 3224
medicine, general & internal (3220) 3220
stroke (2987) 2987
anti-inflammatory agents, non-steroidal - therapeutic use (2973) 2973
peripheral vascular disease (2757) 2757
aspirin - pharmacology (2674) 2674
aged, 80 and over (2588) 2588
time factors (2501) 2501
mortality (2341) 2341
therapy (2284) 2284
fibrinolytic agents - therapeutic use (2256) 2256
drug therapy (2246) 2246
low-dose aspirin (2231) 2231
care and treatment (2186) 2186
prospective studies (2105) 2105
hematology (2076) 2076
clinical trials as topic (2051) 2051
platelet aggregation inhibitors - adverse effects (2019) 2019
abridged index medicus (1980) 1980
thrombosis (1967) 1967
anticoagulants (1949) 1949
retrospective studies (1849) 1849
double-blind method (1845) 1845
follow-up studies (1819) 1819
surgery (1760) 1760
platelet aggregation inhibitors - administration & dosage (1756) 1756
nonsteroidal antiinflammatory drugs (1726) 1726
health aspects (1719) 1719
platelet aggregation - drug effects (1718) 1718
warfarin (1714) 1714
pregnancy (1710) 1710
research (1700) 1700
analysis (1697) 1697
stroke - prevention & control (1682) 1682
cardiovascular disease (1678) 1678
myocardial-infarction (1658) 1658
dose-response relationship, drug (1631) 1631
adolescent (1581) 1581
randomized controlled trials as topic (1568) 1568
medicine & public health (1565) 1565
warfarin - therapeutic use (1550) 1550
rats (1538) 1538
anti-inflammatory agents, non-steroidal - adverse effects (1514) 1514
heart attacks (1509) 1509
myocardial infarction - drug therapy (1503) 1503
heparin - therapeutic use (1490) 1490
risk assessment (1458) 1458
antiplatelet therapy (1442) 1442
clinical neurology (1407) 1407
disease (1406) 1406
recurrence (1363) 1363
patients (1362) 1362
acute coronary syndromes (1350) 1350
cardiology (1346) 1346
management (1329) 1329
blood platelets - drug effects (1306) 1306
cardiovascular diseases - prevention & control (1302) 1302
percutaneous coronary intervention (1265) 1265
inflammation (1243) 1243
stents (1239) 1239
secondary prevention (1238) 1238
dipyridamole - therapeutic use (1216) 1216
trial (1188) 1188
dosage and administration (1182) 1182
cardiovascular diseases (1178) 1178
blood platelets (1166) 1166
hemorrhage - chemically induced (1151) 1151
oncology (1147) 1147
prognosis (1125) 1125
platelet aggregation inhibitors - pharmacology (1114) 1114
studies (1111) 1111
thrombosis - prevention & control (1109) 1109
inhibition (1108) 1108
clinical trials (1100) 1100
coronary heart disease (1099) 1099
cancer (1096) 1096
child (1090) 1090
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (12) 12
Online Resources - Online (8) 8
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (31721) 31721
German (901) 901
French (723) 723
Russian (343) 343
Spanish (342) 342
Japanese (332) 332
Italian (306) 306
Chinese (152) 152
Dutch (96) 96
Polish (95) 95
Danish (57) 57
Portuguese (54) 54
Norwegian (33) 33
Czech (32) 32
Swedish (32) 32
Finnish (31) 31
Hungarian (30) 30
Hebrew (21) 21
Turkish (20) 20
Romanian (19) 19
Korean (18) 18
Ukrainian (17) 17
Serbian (15) 15
Croatian (14) 14
Bulgarian (12) 12
Slovak (9) 9
Lithuanian (8) 8
Bosnian (2) 2
Afrikaans (1) 1
Arabic (1) 1
Catalan (1) 1
Icelandic (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 496 - 503
Summary In March, 2010, a group of breast cancer experts met to develop a consensus statement on breast cancer prevention, with a focus on medical and therapeutic interventions... 
Hematology, Oncology and Palliative Medicine | ZOLEDRONIC ACID | SURGICAL ADJUVANT BREAST | ONCOLOGY | STATIN USE | LOW-DOSE TAMOXIFEN | RANDOMIZED-TRIAL | FOLLOW-UP | RISK | BOWEL PROJECT | POSTMENOPAUSAL WOMEN | GENOME-WIDE ASSOCIATION | Thiophenes - therapeutic use | Metformin - therapeutic use | Raloxifene Hydrochloride - therapeutic use | Humans | Selective Estrogen Receptor Modulators - adverse effects | Tetrahydronaphthalenes - therapeutic use | Pyrrolidines - therapeutic use | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Estrogen Receptor Modulators - therapeutic use | Retinoids - therapeutic use | Selective Estrogen Receptor Modulators - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Female | Aromatase Inhibitors - therapeutic use | Estrogen Receptor Modulators - adverse effects | Anticarcinogenic Agents - therapeutic use | Triazoles - therapeutic use | Premenopause | Anastrozole | Consensus Development Conferences as Topic | Breast Neoplasms - prevention & control | Fenretinide - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Piperidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Tamoxifen - therapeutic use | Androstadienes - therapeutic use | Expert Testimony | Norpregnenes - therapeutic use | Nitriles - therapeutic use | COX-2 inhibitors | Care and treatment | Aspirin | Oncology, Experimental | Menopause | Phosphonates | Breast cancer | Retinoids | Research | Tamoxifen | Prevention | Analysis | Health aspects | Cancer
Journal Article
European heart journal, ISSN 0195-668X, 2003, Volume 24, Issue 5, pp. 464 - 474
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 611 - 621
.... Anticoagulation uses 1 of 4 choices: bivalirudin, unfractionated heparin, enoxaparin, and fondaparinux... 
Cardiovascular | WORKING GROUP | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTITHROMBOTIC THERAPY | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | EUROPEAN-SOCIETY | ELEVATION MYOCARDIAL-INFARCTION | CONSENSUS DOCUMENT | PLATELET REACTIVITY | ATRIAL-FIBRILLATION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes
Journal Article
Circulation, ISSN 0009-7322, 2015, Volume 131, Issue 17, pp. 1486 - 1494
Background Our aim was to describe the incidence and predictors of stroke in patients who have heart failure without atrial fibrillation (AF). Methods and... 
Heart failure | Stroke | Sinus rhythm | Atrial fibrillation | Risk factors | Ventricular ejection fraction | heart failure | risk factors | CARDIAC & CARDIOVASCULAR SYSTEMS | VENTRICULAR SYSTOLIC FUNCTION | RANDOMIZED-TRIAL | NATRIURETIC PEPTIDE | stroke | ASPIRIN | atrial fibrillation | CONVERTING-ENZYME INHIBITORS | THERAPY | WARFARIN | EJECTION FRACTION | ventricular ejection fraction | sinus rhythm | PERIPHERAL VASCULAR DISEASE | CANDESARTAN | THROMBOEMBOLISM | Follow-Up Studies | Humans | Middle Aged | Male | Diabetes Mellitus, Type 1 - complications | Peptide Fragments - blood | Aged, 80 and over | Adult | Female | Stroke - epidemiology | Natriuretic Peptide, Brain - blood | Benzimidazoles - therapeutic use | Heart Failure - complications | Stroke - prevention & control | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Rosuvastatin Calcium | Biomarkers - blood | Heart Failure - drug therapy | Randomized Controlled Trials as Topic | Stroke Volume | Cardiovascular Agents - therapeutic use | Stroke - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Atrial Fibrillation - etiology | Fatty Acids, Omega-3 - therapeutic use | Tetrazoles - therapeutic use | Aged | Fluorobenzenes - therapeutic use | Fatty Acids | Peptide Fragments/ blood | Omega-3/ therapeutic use | Tetrazoles/therapeutic use | Sulfonamides/ therapeutic use | Kardiologi | 80 and over | Biological Markers/blood | Natriuretic Peptide | Pyrimidines/ therapeutic use | Cardiovascular Agents/therapeutic use | Stroke/epidemiology/ etiology/prevention & control | Benzimidazoles/therapeutic use | Diabetes Mellitus | Type 1/complications | Brain/ blood | Cardiac and Cardiovascular Systems | Atrial Fibrillation/etiology | Fluorobenzenes/ therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/ therapeutic use | Heart Failure/complications/ drug therapy
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 01/2019, Volume 2019, Issue 1, p. CD005431
Background Traumatic hyphema is the entry of blood into the anterior chamber (the space between the cornea and iris) subsequent to a blow or a projectile... 
Aspirin | Bed Rest | Bandages | Patient Positioning | Adrenal Cortex Hormones | Hyphema | Eye Injuries | Tranexamic Acid | Visual Acuity | Randomized Controlled Trials as Topic | Wounds, Nonpenetrating | Antifibrinolytic Agents | Mydriatics | Platelet Aggregation Inhibitors | Estrogens, Conjugated (USP) | Eyes & vision | Medicine General & Introductory Medical Sciences | Aminocaproic Acid | Adrenal Cortex Hormones [therapeutic use] | Aspirin [therapeutic use] | Humans | Platelet Aggregation Inhibitors [therapeutic use] | SECONDARY HEMORRHAGE | MEDICINE, GENERAL & INTERNAL | Patient Positioning [methods] | STREPTOKINASE | SICKLED ERYTHROCYTES | Hyphema [etiology; therapy] | GLAUCOMA | Estrogens, Conjugated ( USP) [therapeutic use] | TOPICAL AMINOCAPROIC ACID | RISK | Wounds, Nonpenetrating [complications] | CHILDREN | TRANEXAMIC ACID | Mydriatics [therapeutic use] | Aminocaproic Acid [therapeutic use] | OUTPATIENT MANAGEMENT | Antifibrinolytic Agents [therapeutic use] | UROKINASE | Antifibrinolytic Agents - therapeutic use | Wounds, Nonpenetrating - complications | Eye Injuries - complications | Tranexamic Acid - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Mydriatics - therapeutic use | Estrogens, Conjugated (USP) - therapeutic use | Patient Positioning - methods | Aminocaproic Acid - therapeutic use | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Child | Hyphema - therapy | Hyphema - etiology
Journal Article
PharmacoEconomics, ISSN 1170-7690, 7/2010, Volume 28, Issue 7, pp. 521 - 538
Total hip and knee replacements (THR and TKR) are high-risk settings for venous thromboembolism (VTE). This review summarizes the cost effectiveness of VTE... 
Quality of Life Research | Health Economics | Health Administration | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | Research-and-development | Tinzaparin-sodium, therapeutic use | Warfarin, therapeutic use | Dabigatran-etexilate, therapeutic use | Dalteparin-sodium, therapeutic use | Factor-Xa-inhibitors, therapeutic use | Antithrombotics, therapeutic use | Anticoagulants, therapeutic use | Deep-vein-thrombosis, Prevention | Enoxaparin-sodium, therapeutic use | Fondaparinux-sodium, therapeutic use | Rivaroxaban, therapeutic use | Low-molecular-weight-heparins, therapeutic use | Ardeparin-sodium, therapeutic use | Pulmonary-embolism, Prevention | Cost-effectiveness | REVISION HIP | PROLONGED ENOXAPARIN THERAPY | DEEP-VEIN THROMBOSIS | POSTOPERATIVE FONDAPARINUX | ANTITHROMBOTIC PROPHYLAXIS | DABIGATRAN ETEXILATE | MOLECULAR-WEIGHT HEPARIN | HEALTH CARE SCIENCES & SERVICES | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | ELECTIVE HIP | PHARMACOLOGY & PHARMACY | HEALTH POLICY & SERVICES | ECONOMICS | Anticoagulants; therapeutic use; Antithrombotics; therapeutic use; Ardeparin-sodium; therapeutic use; Cost-effectiveness; Dabigatran-etexilate; therapeutic use; Dalteparin-sodium; therapeutic use; Deep-vein-thrombosis; Prevention; Enoxaparin-sodium; therapeutic use; Factor-Xa-inhibitors; therapeutic use; Fondaparinux-sodium; therapeutic use; Low-molecular-weight-heparins; therapeutic use; Pulmonary-embolism; Prevention; Research-and-development; Rivaroxaban; therapeutic use; Tinzaparin-sodium; therapeutic use; Warfarin; therapeutic use | Warfarin | Aspirin | Care and treatment | Thrombin | Cost benefit analysis | Pulmonary embolism | Orthopedic surgery | Angiogenesis inhibitors | Diagnosis | Salicylates | Thromboembolism | Health aspects | Medical care, Cost of | Studies | Anticoagulants | Literature | Joint replacement surgery | Thrombosis | Pharmaceuticals
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | WARFARIN | REGIMENS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article